The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Launches collaborative centre for translational research in head and neck cancer
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The 200 bedded hospital owned & operated by Alexis
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Subscribe To Our Newsletter & Stay Updated
